EULAR 2019: Samsung Bioepis and Biogen stage renewed push for anti-TNF biosimilars

12 June 2019

The chance to persuade European rheumatologists and other healthcare practitioners to switch to or prescribe from the outset their anti-TNF biosimilars make EULAR a highly important event for Samsung Bioepis and Biogen (Nasdaq: BIIB).

So it is no surprise that plenty of data is being presented again this year by the partners, which are the first in Europe to have available biosimilars referencing the three most prescribed anti-TNF biologics and already have around 145,000 patients on their treatments.

The abstracts include real-world data on Benepali, a biosimilar of Amgen’s (Nasdaq: AMGN) Enbrel (etanercept), Flixabi, which references Janssen’s Remicade (infliximab) and Imraldi, a copy of AbbVie’s (NYSE: ABBV) mega blockbuster Humira (adalimumab).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK